Caris Life Sciences Reports Quarterly Results for Quarter Ended September 30

Caris Life Sciences, Inc. reported third-quarter 2026 revenue of $275.4 million, representing a 27% increase year-over-year and surpassing the FactSet consensus estimate of $255.4 million. The company also posted earnings per share of $0.05, beating the expected $0.03. Growth was driven by an increase in clinical case volume, which rose by approximately 21%, and improvements in average selling price. Following these results, the company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion. While the company recorded a net income of $15.3 million and an adjusted EBITDA of $44.4 million, it reported an operating cash flow of -$22.2 million for the quarter.